Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment

Neuroscience Letters

Volumn 414, Issue 1, 2007, Pages 61-64

  Brunstein, M G ^a,c   Silveira Jr , E M ^a   Chaves, L S ^a   Machado, H ^b   Schenkel, O ^b   Belmonte de Abreu, P ^a   Souza, D O ^c   Lara, D R ^d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Laboratorio Weinmann   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

5 Nucleotidase; Adenosine; Adenosine deaminase; Antipsychotics; Purinergic system; Schizophrenia

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; CLOZAPINE; INOSINE; NEUROLEPTIC AGENT;

ADULT; AMINO ACID METABOLISM; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GROUPS BY AGE; HUMAN; MALE; PRIORITY JOURNAL; RACE; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; UPREGULATION; VOLUNTEER;

5'-NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BRAIN; CLOZAPINE; DRUG RESISTANCE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; UP-REGULATION;

EID: 33846925498     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.11.071     Document Type: Article

References (26)

1. Akhondzadeh S., Safarcherati A., and Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 253-259
2. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., and Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 25 (2000) 131-137
3. Brundege J.M., and Dunwiddie T.V. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv. Pharmacol. 39 (1997) 353-391
4. Brunstein M.G., Ghisolfi E.S., Ramos F.L., and Lara D.R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry 66 (2005) 213-219
5. Dall'Igna O.P., Da Silva A.L., Dietrich M.O., Hoffmann A., de Oliveira R.V., Souza D.O., and Lara D.R. Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-d-aspartate receptor antagonist MK-801 in mice. Psychopharmacology (Berl.) 166 (2003) 258-263
6. de Oliveira R.V., Dall'Igna O.P., Tort A.B., Schuh J.F., Neto P.F., Santos Gomes M.W., Souza D.O., and Lara D.R. Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. Behav. Pharmacol. 16 (2005) 79-84
7. Ellis G., and Goldberg D.M. A reduced nicotinamide adenine dinucleotide-linked kinetic assay for adenosine deaminase activity. J. Lab. Clin. Med. 76 (1970) 507-517
8. Flyckt L., Venizelos N., Edman G., Bjerkenstedt L., Hagenfeldt L., and Wiesel F.A. Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Arch. Gen. Psychiatry 58 (2001) 953-958
9. Franco R., Casado V., Ciruela F., Saura C., Mallol J., Canela E.I., and Lluis C. Cell surface adenosine deaminase: much more than an ecto-enzyme. Prog. Neurobiol. 52 (1997) 283-294
10. Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmonte-de-Abreu P., Souza D.O., and Lara D.L. The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology 27 (2002) 620-637
11. Ghisolfi E.S., Schuch A., Strimitzer Jr. I.M., Luersen G., Martins F.F., Ramos F.L., Becker J., and Lara D.R. Caffeine modulates P50 auditory sensory gating in healthy subjects. Eur. Neuropsychopharmacol. 16 (2006) 204-210
12. Golembiowska K., and Zylewska A. Effect of adenosine kinase, adenosine deaminase and transport inhibitors on striatal dopamine and stereotypy after methamphetamine administration. Neuropharmacology 39 (2000) 2124-2132
13. Herken H., Akyol O., Yilmaz H.R., Tutkun H., Savas H.A., Ozen M.E., Kalenderoglu A., and Gulec M. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum. Psychopharmacol. 21 (2006) 53-59
14. Horrobin D.F. The membrana phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Res. 30 (1998) 193-208
15. Kay S.R., Opler L.A., Lindenmayer J.P., and The Positive. Negative syndrome scale (PANSS): rationale and standardization. Br. J. Psychiatry 7 (1989) S59-S67
16. Keshavan M.S., Reynolds III C.F., Miewald M.J., Montrose D.M., Sweeney J.A., Vasko Jr. R.C., and Kupfer D.J. Delta sleep deficits in schizophrenia: evidence from automated analyses of sleep data. Arch. Gen. Psychiatry 5 (1998) 443-448
17. Landolt H.P., Dijk D.J., Gaus S.E., and Borbely A.A. Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology 12 (1995) 229-238
18. Lara D.R., Brunstein M.G., Ghisolfi E.S., Lobato M.I., Belmonte-de-Abreu P., and Souza D.O. Allopurinol augmentation for poorly responsive schizophrenia. Int. Clin. Psychopharmacol. 16 (2001) 235-237
19. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., and Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 617-629
20. Lara D.R., and Souza D.O. Schizophrenia: a purinergic hypothesis. Med. Hypotheses 54 (2000) 157-166
21. Lara D.R., Vianna M.R., Paris F., Quevedo J., Oses J.P., Battastini A.M.O., Sarkis J.J.F., and Souza D.O. Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5′-nucleotidase activity in rats. Neuropsychobiology 44 (2001) 99-102
22. Moriwaki Y., Yamamoto T., and Higashino K. Enzymes involved in purine metabolism-a review of histochemical localization and functional implication. Histol. Histopathol. 14 (1999) 1321-1340
23. Ozyurt B., Sarsilmaz M., Akpolat N., Ozyurt H., Akyol O., Herken H., and Kus I. The protective effects of omega-3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochem. Int. September (2006) (Epub ahead of print)
24. Reddy P.L., Khanna S., Subhash M.N., Channabasavanna S.M., and Rao B.S. CSF amine metabolite in depression. Biol. Psychiatry 31 (1992) 112-118
25. Rétey J.V., Adam M., Honegger E., Khatami R., Luhmann U.F., Jung H.H., Berger W., and Landolt H.P. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 15676-15681
26. Zimmermannn H., Braun N., Kegel B., and Heine P. New insights into the molecular strucutre and function of ecto-nucleotidases in the nervous system. Neurochem. Int. 32 (1998) 421-425